This bill amends Title II of the Social Security Act to remove the statutory waiting periods that delay federal disability insurance benefits and Medicare coverage for people diagnosed with metastatic breast cancer. It does so by adding the words “metastatic breast cancer” alongside the current exception for amyotrophic lateral sclerosis (ALS), creating the same expedited entitlement pathway.
The change speeds beneficiaries’ access to monthly SSDI cash benefits (which are normally subject to a five-month waiting period) and waives the 24-month Medicare waiting period that typically follows SSDI entitlement. Accelerated access alters billing, eligibility and program-cost dynamics for the Social Security Administration (SSA), Centers for Medicare & Medicaid Services (CMS), providers, and payers, and raises practical questions about diagnosis verification and administrative implementation.
At a Glance
What It Does
The bill inserts “metastatic breast cancer” into the same statutory text that currently treats ALS as an exception to both the SSDI five-month waiting period and the 24-month Medicare waiting period following SSDI entitlement. It therefore eliminates those waits for qualifying metastatic breast cancer claimants.
Who It Affects
Directly affects individuals diagnosed with metastatic breast cancer who file for SSDI, the SSA disability determination system that adjudicates claims, and CMS administration of Medicare enrollment and coverage. It also touches hospitals, oncology clinics, private disability insurers, and federal program budgets.
Why It Matters
It follows the ALS precedent to prioritize immediate access to benefits for a condition with serious morbidity and mortality, changing timing of payments and coverage rather than benefit eligibility. For compliance officers and program managers, the bill signals the need for new documentation standards, revised claims processes, and budgetary planning.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes two narrowly focused statutory edits. First, it amends the Social Security Act provision that governs eligibility timing for disability insurance benefits so that people with metastatic breast cancer are no longer subject to the usual initial waiting period before monthly SSDI checks begin.
Practically, that removes the first five months of the standard SSDI waiting period for this population, enabling cash benefits to begin sooner once the individual is found disabled and entitled.
Second, the bill amends the rule that currently requires most SSDI beneficiaries to wait 24 months from SSDI entitlement before they become eligible for Medicare (Parts A and B). By adding metastatic breast cancer to the statute’s ALS exception, the bill lets qualifying metastatic breast cancer beneficiaries receive Medicare coverage without the usual two-year delay.Both changes are implemented by inserting the phrase “metastatic breast cancer” next to the existing ALS exception in two places in Title II (the SSDI entitlement timing provision and the Medicare waiting-period provision).
The bill specifies that the SSDI waiting-period change applies to applications filed after enactment, while the Medicare waiver applies to benefits for months beginning after enactment. The text does not add new funding, define evidentiary standards for establishing metastatic disease, or alter the medical-vocational criteria SSA uses to determine disability; it only changes timing of entitlement and enrollment.
The Five Things You Need to Know
The bill amends 42 U.S.C. 423(a) by inserting “metastatic breast cancer” into the statutory language that creates the ALS exception to the SSDI waiting period.
It also amends 42 U.S.C. 426(h) to waive the 24-month SSDI-to-Medicare waiting period for beneficiaries with metastatic breast cancer, matching the ALS treatment.
The SSDI waiting-period elimination applies only to applications filed after the law’s enactment; the Medicare waiver applies to months beginning after enactment.
The bill does not change SSA’s disability standard (medical-vocational adjudication); it changes only the timing of benefit and Medicare entitlement once SSA finds a claimant disabled.
Congress used the existing ALS statutory exception as the model — the bill adds metastatic breast cancer to the same narrow exception rather than creating a separate, new eligibility category or funding stream.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the Act the public name “Metastatic Breast Cancer Access to Care Act.” This is purely captioning; it has no substantive effect on eligibility or administration but sets the bill’s stated policy objective.
Eliminate SSDI waiting period for metastatic breast cancer
Alters section 223(a) of the Social Security Act by adding “metastatic breast cancer” to the textual exception that already covers ALS, and adjusts paragraph numbering to accommodate the insertion. Operationally, this removes the initial waiting period that otherwise delays the start of monthly SSDI benefits. The provision is limited to applications filed after enactment, so SSA will need to update claims intake materials and internal policy guidance to apply the new rule prospectively.
Waive 24-month Medicare waiting period
Amends section 226(h) to subject beneficiaries with metastatic breast cancer to the same Medicare-entitlement timing as ALS beneficiaries. That means individuals who are entitled to SSDI based on metastatic breast cancer will not have to complete the typical 24-month Medicare waiting period before starting Medicare Parts A and B. The amendment takes effect for months beginning after enactment, requiring CMS to update enrollment rules and coordinate with SSA for immediate Medicare eligibility when DSS finds entitlement.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People diagnosed with metastatic breast cancer: they gain faster access to SSDI cash payments and to Medicare coverage, reducing gaps in income and health coverage shortly after entitlement.
- Caregivers and families of affected patients: earlier benefit and coverage starts can ease immediate financial and care burdens by providing payments and a payer for services sooner.
- Oncology clinics and hospitals treating metastatic breast cancer patients: Medicare coverage begins earlier for eligible patients, reducing reliance on hospital charity care or uncompensated billing for costly cancer treatments.
- Patient advocacy and support organizations focused on metastatic breast cancer: the bill advances a concrete policy objective they commonly pursue—shortening the time between diagnosis and public benefit access—and increases their leverage in implementation discussions.
Who Bears the Cost
- Medicare program (CMS) and the Medicare trust funds: earlier enrollment increases near-term Medicare spending for Parts A and B for this group and may raise projected outlays absent offsets.
- Social Security Administration (disability adjudication offices): SSA will face implementation work—revising policy, training adjudicators, and handling potentially increased application volumes—which may require administrative resources.
- State Disability Determination Services (DDS): DDS offices may see a rise in complex medical documentation requests and expedited processing demands to establish entitlement sooner.
- Hospitals and providers in the short term: while Medicare coverage reduces uncompensated care, providers may need to adjust billing workflows and prior-authorization processes to reflect earlier Medicare as primary payer.
- Private disability insurers and employer-sponsored short-term disability programs: changes in timing for public SSDI payments could shift coordination of benefits and alter claim patterns, potentially complicating private claim administration.
Key Issues
The Core Tension
The central dilemma is between speeding access to benefits for a medically serious, often fast-progressing condition and managing federal program costs and administrative integrity: quick entitlement improves care and financial security for patients but raises questions about how to verify diagnoses reliably, how to prevent inconsistent adjudication or misuse, and how to fund the accelerated costs and added agency workload.
The bill is narrowly drafted to change timing, not medical eligibility, but it leaves critical implementation questions unaddressed. It does not define what medical documentation suffices to prove metastatic breast cancer for expedited treatment; SSA and CMS will need to decide whether pathology reports, imaging, oncologist attestations, or cancer registry entries will trigger the exception.
Absent clear standards, adjudicators could face inconsistent decisions, appeals, and delays that undermine the bill’s purpose.
Fiscal and administrative trade-offs are also unresolved. Waiving waiting periods accelerates expenditures into the near term for both SSDI payments and Medicare coverage.
The bill contains no offsets or appropriations for SSA and CMS to handle increased workload, so agencies must absorb implementation costs or seek additional funds. Finally, the change interacts imperfectly with private coverage and Medicaid: it may shift who pays for expensive cancer care, create coordination-of-benefits complexity, and prompt insurers to change plan designs or prior-authorization rules in response to earlier public coverage.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.